Costs and health care resource utilization among chronic obstructive pulmonary disease patients with newly acquired pneumonia

ClinicoEconomics and Outcomes Research

Volumn 6, Issue 1, 2014, Pages 349-356

  Lin, Junji ^a   Li, Yunfeng ^b   Tian, Haijun ^b   Goodman, Michael J ^a   Gabriel, Susan ^b   Nazareth, Tara ^b   Turner, Stuart J ^b,c   Arcona, Stephen ^b   Kahler, Kristijan H ^b  

^a UNIVERSITY OF UTAH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

COPD; Cost effectiveness economics; Health care costs; Outcomes research

Indexed keywords

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; COST OF ILLNESS; DISEASE ASSOCIATION; DRUG COST; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION COST; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PNEUMONIA; PRESCRIPTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM;

EID: 84904409271     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S65824     Document Type: Article

References (26)

1. The World Health Report 2000. Health Systems: Improving Performance. Available from: http://www. who. int/whr/2000/en/whr00_en. pdf. Geneva: World Health Organization; 2000. Accessed July 17, 2013.
2. Yawn BP, Li Y, Tian H, Zhang J, Arcona S, Kahler KH. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. Int J Chron Obstruct Pulmon Dis. 2013; 8: 295-304.
3. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med. 2007; 176(2): 162-166.
4. Marzoratti L, Iannella HA, Waterer GW. Inhaled corticosteroids and the increased risk of pneumonia. Ther Adv Respir Dis. 2013; 7(4): 225-234.
5. Price D, Yawn B, Brusselle G, Rossi A. Risk-to-benefit ratio of inhaled corticosteroids with COPD. Prim Care Respir J. 2013; 22(1): 92-100.
6. Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J. 2009; 34(3): 641-647.
7. Calverley PM, Stockley RA, Seemungal TA, et al; Investigating New Standards for Prophylaxis in Reduction of Exacerbations (INSPIRE) Investigators. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest. 2011; 139(3): 505-512.
8. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006; 367(9524): 1747-1757.
9. Ewig S, Birkner N, Strauss R, et al. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax. 2009; 64(12): 1062-1069.
10. Holguin F, Folch E, Redd SC, Mannino DM. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest. 2005; 128(4): 2005-2011.
11. Polsky D, Bonafede M, Suaya JA. Comorbidities as a driver of the excess costs of community-acquired pneumonia in US commercially-insured working age adults. BMC Health Serv Res. 2012; 12: 379.
12. Liu SX, Lee MC, Atakhorrami M, et al. Economic assessment of home-based COPD management programs. COPD. 2013; 10(6): 640-649.
13. Breunig IM, Shaya FT, Scharf SM. Delivering cost-effective care for COPD in the USA: recent progress and current challenges. Expert Rev Pharmacoecon Outcomes Res. 2012; 12(6): 725-731.
14. Birnbaum HG, Morley M, Greenberg PE, Cifaldi M, Colice GL. Economic burden of pneumonia in an employed population. Arch Intern Med. 2001; 161(22): 2725-2731.
15. Örnek T, Tor M, Altin R, et al. Clinical factors affecting the direct cost of patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease. Int J Med Sci. 2012; 9(4): 285-290.
16. Truven Health Analytics [homepage on the Internet]. Ann Arbor, MI: Truven Health Analytics Inc.; 2012. Available from: http://truvenhealth. com/your_healthcare_focus/research/marketscan_research_databases. aspx. Accessed July 17, 2013.
17. Centers for Disease Control and Prevention [homepage on the Internet]. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). Atlanta, GA: Centers for Disease Control and Prevention; 2014. Available from: http://www. cdc. gov/nchs/icd/icd9cm. htm. Accessed September 3, 2013.
18. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006; 28(3): 523-532.
19. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45(6): 613-619.
20. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009; 28(25): 3083-3107.
21. Baser O, Crown WH, Pollicino C. Guidelines for selecting among different types of bootstraps. Curr Med Res Opin. 2006; 22(4): 799-808.
22. Chronic Obstructive Pulmonary Disease (COPD) Includes: Chronic Bronchitis and Emphysema [webpage on the Internet]. Atlanta, GA: Centers for Disease Control and Prevention; 2012 [updated May 14, 2014]. Available from: http://www. cdc. gov/nchs/fastats/copd. htm. Accessed July 17, 2013.
23. Yu H, Rubin J, Dunning S, Li S, Sato R. Clinical and economic burden of community-acquired pneumonia in the Medicare fee-for-service population. J Am Geriatr Soc. 2012; 60(11): 2137-2143.
24. Broulette J, Yu H, Pyenson B, Iwasaki K, Sato R. The incidence rate and economic burden of community-acquired pneumonia in a working-age population. Am Health Drug Benefits. 2013; 6(8): 494-503.
25. Müllerova H, Chigbo C, Hagan GW, et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med. 2012; 106(8): 1124-1133.
26. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease (GOLD) [updated 2014]. Available from: http://www. goldcopd. org/guidelines-global-strategy-for-diagnosis-management. html. Accessed April 7, 2014.